Reagent Problem Could Have Affected Rosetta Genomics' Cancer Test Results
November 10, 2010
Reagent Problem Could Have Affected Rosetta Genomics' Cancer Test Results
In a document filed with the SEC, the Israeli firm disclosed that problems with a reagent used for testing could have affected results for about 100 miRview mets tests performed in the company's CLIA laboratory between August and October.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Rosetta Gets Medicare Coverage for mets2 Assay; Stock Soars
May 16, 2012 / GenomeWeb Daily News - Rosetta Revises Deal with Precision to Co-market miRview mets2
October 17, 2012 / GenomeWeb Daily News - Prospective Study Suggests Site-Specific Treatment after BioTheranostics' CUP Testing Improves Survival
October 17, 2012 / Pharmacogenomics Reporter - Rosetta Publishes Data on Cancer of Unknown Primary Origin Test
May 31, 2012 / Gene Silencing News - Rosetta Gets NY State Approval for Tumor Test
December 9, 2011 / GenomeWeb Daily News